Abstract:Multiple myeloma (MM) is an incurable B-cell malignancy. High-dose chemotherapy with stem cell support has achieved higher response rates than conventional therapy, but few patients remain in long-term remission. Arsenic trioxide (As2O3) is an effective treatment for acute promyelocytic leukemia. Current clinical studies are investigating arsenic as a therapeutic agent for malignancies. The mechanism of cytotoxicity inducted by As2O3 has not been known thoroughly. Constitutively activated NF-κB is a characteristic of different tumor entities including MM clones and malignant plasma cells from MM patients. It plays an important role in maintaining tumor cell proliferation and protecting cell from apoptosis. The study was to explore the possible mechanism of As2O3 effects on MM lines. Materials and methods: The human MM cell lines of KM3 and RPMI8226 were provided by Hematology Institution of Zhejiang University. The concentration of As2O3 in cell culture system was from 0.5μmol/L to 20μmol/L, 24 hours was selected as the termination point of cell culture. Cell culture without As2O3 and first-antibody-dismissed test were enrolled as controls. Both of the MM lines were treated with As2O3 in various concentrations. The restrained proliferation was observed by drawing growth curve. MTT bioassay was used to examine the effect of As2O3 on cell growth and the concentration of 50% growth inhibition( IC50) calculated respectively. Apoptosis and changes of IκB-α protein was observed by flow cytometry(FCM). Changes and subcellular localization of IκB-α protein were observed by fluorescence microscopy. Western blot was also used to analyze the expression of NF-κB in nuclear. Results: As2O3 inhibited the proliferation of both MM lines, and IC50 of KM3 and RPMI8226 was 9.61μmol/L and 8.01μmol/L respectively. After exposure to As2O3, both of the lines were induced to apoptosis. With As2O3 concentration varied from 0.5μmol/L to 20μmol/L the apoptosis rate of KM3 and RPMI8226 was concentration-dependent measured by FCM. After 24 hours treated with 20μmol/L As2O3, the apoptosis rate of KM3 cells was 41.18% while that of RPMI8226 was 65.25%. It seemed that RPMI8226 cell was more sensitive to As2O3. FCM analysis showed a significant increase in the percentage of G2/M phase cells, from 13.74% to 41.72%, and a decrease percentage of S phase cells from 35.11% to 23.96%. The level of IκB-α in cytoplasm was down-regulated after As2O3 stimulation in both cell lines. The down-regulation of IκB-α from 79.68% to 51.57% was confirmed by FCM in KM3 treated with 10μmol/L As2O3 (p<0.01), the effect was concentration-dependent. While the IκB-α in RPMI8226 changed from 79.72% to 34.08% (p<0.01). Immunofluorescence assay showed that IκB-α localized in cytoplasm mostly. The level of IκB-α protein was down-regulated after As2O3 stimulation. The results showed that KM3 and RPMI8226 lines expressed constitutively activity NF-κB and As2O3 down-regulated the constitutive expression of NF-κB in both cell lines but with different kinetics. Conclusions: As2O3 could not only inhibit the proliferation but also induce apoptosis of KM3 and RPMI8226 cells. The mechanisms of its effect on MM cells may include decreasing the constitutive activity of NF-κB, subsequently down-regulating the expression of various gene products controlled by NF-κB, thus inducing apoptosis in MM cells. As2O3 could inhibit the proliferation of MM cells by changing MM cell cycle and inducing G2/M phase arrest.

Arsenic Trioxide Inhibits Ewing’s Sarcoma Cell Invasiveness by Targeting P38mapk and C-Jun N-terminal Kinase

Inhibition of Arsenic Trioxide for the Capability of Migration and Invasion in Ewing' S Sarcoma Cell in Vitro

Arsenic Circumvents the Gefitinib Resistance by Binding to P62 and Mediating Autophagic Degradation of EGFR in Non-Small Cell Lung Cancer

Arsenic Trioxide as an Inducer of Apoptosis and Down-regulation of EWS-FLi1 Fusion Protein in Ewing Sarcoma

Arsenic Trioxide Inhibits Osteosarcoma Cell Invasiveness Via MAPK Signaling Pathway

Arsenic Trioxide Induces Not Only Apoptosis but Also Autophagic Cell Death in Leukemia Cell Lines Via Up-Regulation of Beclin-1

Mechanism Of Arsenic Trioxide-Induced Apoptosis On Multiple Myeloma Cells.

The effect of arsenic trioxide on metastasis and invasion of human osteosarcoma cell

Decrease in stathmin expression by arsenic trioxide inhibits the proliferation and invasion of osteosarcoma cells via the MAPK signal pathway

Arsenic trioxide inhibits the growth of Adriamycin resistant osteosarcoma cells through inducing apoptosis

The Inhibition of Growth and Angiogenesis in Heterotransplanted Esophageal Carcinoma Via Intratumoral Injection of Arsenic Trioxide

Effects of arsenic trioxide on the pancreatic carcinoma cell line PC-3 and inhibitory migration

Intratumoral injection of arsenic to enhance antitumor efficacy in human esophageal carcinoma cell xenografts.

Arsenic sulfide induces apoptosis and autophagy through the activation of ROS/JNK and suppression of Akt/mTOR signaling pathways in osteosarcoma.

Arsenic trioxide promotes ERK1/2-mediated phosphorylation and degradation of BIMEL to attenuate apoptosis in BEAS-2B cells

Induction of the Mesenchymal to Epithelial Transition by Demethylation- Activated Microrna-200C is Involved in the Anti-Migration/invasion Effects of Arsenic Trioxide on Human Breast Cancer Cells.

Arsenic trioxide inhibits EMT in hepatocellular carcinoma by promoting lncRNA MEG3 via PKM2.

[Preliminary Report of Combination Chemotherapy Including Arsenic Trioxide for Stage III Osteosarcoma and Ewing Sarcoma].

Radiation Enhancement on Fibrosarcoma Cells by Arsenic Trioxide

Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing’s sarcoma via inhibition of cell migration

An Evidence-based Perspective of Arsenic Trioxide (As<sub>2</sub>O<sub>3</sub>) for Cancer Patients